AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September?

AbbVie is presented as the stronger dividend purchase versus Pfizer, supported by $18 billion in free cash flow, a 2.6% dividend yield, and a Dividend King record of more than 50 consecutive annual dividend increases. Its Rinvoq and Skyrizi products generated a combined $8 billion of the company's $16 billion in recent quarterly net revenue, helping offset Humira's loss of exclusivity. Pfizer offers a higher 6.2% yield and reported 18% operational revenue growth among selected recently launched and acquired products, but remains a less certain turnaround story with periodic losses.

Analysis

The relevant dispersion is not dividend yield but cash-flow visibility. ABBV should retain a valuation premium if its post-Humira franchises continue to offset erosion while preserving operating leverage; PFE’s higher yield will not protect the equity if oncology launch costs, deal amortization, or weaker vaccine demand delay sustainable earnings conversion. Income-oriented flows can temporarily support PFE, but a payout perceived as consuming balance-sheet flexibility typically produces multiple compression rather than a durable rerating.

Competitive risk is asymmetric: ABBV’s immunology assets face payer formulary pressure and increasingly aggressive rebate competition, so prescription growth without net-price disclosure is insufficient. PFE’s upside depends more on commercial execution in crowded oncology categories, where competitors including AZN, MRK, LLY and GILD can raise promotional intensity and reduce the value of its pipeline optionality. Over the next one to three quarters, net sales guidance, gross-margin progression, and leverage reduction matter more to relative performance than either company’s stated commitment to capital returns.

Consensus may be too quick to treat PFE as a simple deep-value income recovery and ABBV as a defensive compounder. The contrarian risk to ABBV is that a premium multiple leaves little room for even modest immunology deceleration; the contrarian opportunity in PFE emerges only if management demonstrates that non-COVID growth is translating into recurring free cash flow rather than acquisition-adjusted revenue growth. This article is not itself a catalyst, so position sizing should await earnings evidence rather than retail-dividend demand.

Key Decisions for Investors

• Maintain a 3-6 month relative-value bias: long ABBV / short PFE in equal-dollar size, entered only after confirming ABBV immunology guidance and PFE’s next-quarter operating-margin outlook. Target 8-12% relative return; exit if ABBV cuts franchise guidance or PFE raises full-year adjusted EPS and free-cash-flow expectations materially.
• For ABBV holders, use the next earnings release as a trim trigger if immunology volume growth decelerates while net-price realization weakens; that combination would challenge the premium-defensive thesis before headline revenue does.
• Do not initiate PFE solely for yield. Upgrade to a tactical long only if quarterly non-COVID growth is accompanied by improving operating cash flow and net-debt reduction; absent those data, treat any yield-driven rally as an opportunity to fund the ABBV/PFE pair.
• Monitor XBI versus IHE over the next 1-3 months: sustained XBI outperformance would signal renewed appetite for pipeline optionality and can favor PFE’s rerating case, while IHE leadership supports the higher-quality cash-flow exposure in ABBV.